|
|
Prepublished online as a Blood First Edition Paper on August 8, 2002; DOI 10.1182/blood-2001-12-0269.
 Previous Article | Table of Contents | Next Article 
Blood, 15 December 2002, Vol. 100, No. 13, pp. 4351-4357
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Fludarabine, mitoxantrone, dexamethasone (FND) compared with an
alternating triple therapy (ATT) regimen in patients with stage IV
indolent lymphoma
Apostolia M. Tsimberidou,
Peter McLaughlin,
Anas Younes,
Maria A. Rodriguez,
Fredrick B. Hagemeister,
Andreas Sarris,
Jorge Romaguera,
Mark Hess,
Terry L. Smith,
Ying Yang,
Ana Ayala,
Alejandro Preti,
Ming-Sheng Lee, and
Fernando Cabanillas
From the Department of Lymphoma and Myeloma, University
of Texas, M. D. Anderson Cancer Center, Houston.
Treatment for patients with stage IV indolent lymphoma ranges from
watchful waiting to intensive chemotherapy and stem cell transplantation. In this trial we compared 2 induction regimens followed by 1 year of interferon maintenance therapy. Fludarabine, mitoxantrone (Novantrone), and dexamethasone (FND) were compared with
an alternating triple therapy (ATT) regimen (CHOD-Bleo, ESHAP, and
NOPP). Maintenance interferon/dexamethasone was given for 1 year in
both treatment arms. Endpoints were comparisons of remission rates,
survival, failure-free survival (FFS), molecular response rates, and
toxicities. One hundred forty-two patients with previously untreated stage IV indolent lymphoma were evaluable (73 on FND; 69 on
ATT). The overall response rates were 97% for FND and 97% for ATT
(P = .9). The median follow-up is 5.9 years. The 5-year survival rates were 84% with FND and 82% with ATT
(P = .9); the 5-year FFS rates were 41% with FND and
50% with ATT (P = .02). In a multivariate analysis,
factors predicting for longer FFS were  2-microglobulin
less than 3 mg/L (P = .01) and ATT treatment (P = .03). ATT was associated with a
substantially higher rate of grade 3-4 toxicities than FND. In
conclusion, both regimens were associated with high rates of response
and survival. ATT was associated with substantially longer FFS, but it
was more toxic than FND.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. Montoto, C. Moreno, E. Domingo-Domenech, C. Estany, A. Oriol, A. Altes, J. Besalduch, C. Pedro, S. Gardella, L. Escoda, et al.
High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma
Haematologica,
February 1, 2008;
93(2):
207 - 214.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Moufarij, D. Sampath, M. J. Keating, and W. Plunkett
Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal
Blood,
December 15, 2006;
108(13):
4187 - 4193.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F Cabanillas, I Liboy, O Pavia, and E Rivera
High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication.
Ann. Onc.,
September 1, 2006;
17(9):
1424 - 1427.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q. Liu, L. Fayad, F. Cabanillas, F. B. Hagemeister, G. D. Ayers, M. Hess, J. Romaguera, M. A. Rodriguez, A. M. Tsimberidou, S. Verstovsek, et al.
Improvement of Overall and Failure-Free Survival in Stage IV Follicular Lymphoma: 25 Years of Treatment Experience at The University of Texas M.D. Anderson Cancer Center
J. Clin. Oncol.,
April 1, 2006;
24(10):
1582 - 1589.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. McLaughlin, E. Estey, A. Glassman, J. Romaguera, F. Samaniego, A. Ayala, K. Hayes, A. M. Maddox, H. A. Preti, and F. B. Hagemeister
Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha
Blood,
June 15, 2005;
105(12):
4573 - 4575.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Foussard, P. Colombat, H. Maisonneuve, C. Berthou, R. Gressin, M.-C. Rousselet, P. Rachieru, B. Pignon, B. Mahe, C. Ghandour, et al.
Long-term follow-up of a randomized trial of fludarabine-mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of monoclonal antibodies
Ann. Onc.,
March 1, 2005;
16(3):
466 - 472.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Kaminski, M. Tuck, J. Estes, A. Kolstad, C. W. Ross, K. Zasadny, D. Regan, P. Kison, S. Fisher, S. Kroll, et al.
131I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma
N. Engl. J. Med.,
February 3, 2005;
352(5):
441 - 449.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.S. Czuczman, A. Koryzna, A. Mohr, C. Stewart, K. Donohue, L. Blumenson, Z.P. Bernstein, P. McCarthy, A. Alam, F. Hernandez-Ilizaliturri, et al.
Rituximab in Combination With Fludarabine Chemotherapy in Low-Grade or Follicular Lymphoma
J. Clin. Oncol.,
February 1, 2005;
23(4):
694 - 704.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Baran-Marszak, J. Feuillard, I. Najjar, C. Le Clorennec, J.-M. Bechet, I. Dusanter-Fourt, G. W. Bornkamm, M. Raphael, and R. Fagard
Differential roles of STAT1{alpha} and STAT1{beta} in fludarabine-induced cell cycle arrest and apoptosis in human B cells
Blood,
October 15, 2004;
104(8):
2475 - 2483.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. L. Zinzani, A. Pulsoni, A. Perrotti, S. Soverini, F. Zaja, A. De Renzo, S. Storti, V. M. Lauta, L. Guardigni, P. Gentilini, et al.
Fludarabine Plus Mitoxantrone With and Without Rituximab Versus CHOP With and Without Rituximab As Front-Line Treatment for Patients With Follicular Lymphoma
J. Clin. Oncol.,
July 1, 2004;
22(13):
2654 - 2661.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. S. Velasquez, D. Lew, T. M. Grogan, C. H. Spiridonidis, S. P. Balcerzak, S. R. Dakhil, T. P. Miller, K. S. Lanier, R. A. Chapman, and R. I. Fisher
Combination of Fludarabine and Mitoxantrone in Untreated Stages III and IV Low-Grade Lymphoma: S9501
J. Clin. Oncol.,
May 15, 2003;
21(10):
1996 - 2003.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
